Cardiac Contractility Modulation Attenuates Chronic Heart Failure in a Rabbit Model via the PI3KAKT Pathway

Abstract EN

The Akt plays an important role in regulating cardiac growth, myocardial angiogenesis, and cell death in cardiac myocytes.

However, there are few studies to focus on the responses of the Akt pathway to cardiac contractility modulation (CCM) in a chronic heart failure (HF) model.

In this study, the effects of CCM on the treatment of HF in a rabbit model were investigated.

Thirty six-month-old rabbits were randomly separated into control, HF, and CCM groups.

The rabbits in HF and CCM groups were pressure uploaded, which can cause an aortic constriction.

Then, CCM was gradually injected to the myocardium of rabbits in the CCM group, and this process lasted for four weeks with six hours per day.

Rabbit body weight, heart weight, and heart beating rates were recorded during the experiment.

To assess the CCM impacts, rabbit myocardial histology was examined as well.

Additionally, western blot analysis was employed to measure the protein levels of Akt, FOXO3, Beclin, Pi3k, mTOR, GSK-3β, and TORC2 in the myocardial histology of rabbits.

Results showed that the body and heart weight of rabbits decreased significantly after suffering HF when compared with those in the control group.

However, they gradually recovered after CCM application.

The CCM significantly decreased collagen volume fraction in myocardial histology of HF rabbits, indicating that CCM therapy attenuated myocardial fibrosis and collagen deposition.

The levels of Akt, FOXO3, Beclin, mTOR, GSK-3β, and TORC2 were significantly downregulated, but Pi3k concentration was greatly upregulated after CCM utilization.

Based on these findings, it was concluded that CCM could elicit positive effects on HF therapy, which was potentially due to the variation in the Pi3k/Akt signaling pathway.